[
    [
        {
            "time": "2023-10-18",
            "original_text": "Nearly $300M, six CEOs and dead-ends later, East Bay drugmaker gets date with FDA for migraine treatment",
            "features": {
                "keywords": [
                    "FDA",
                    "migraine treatment",
                    "drugmaker",
                    "East Bay",
                    "dead-ends"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]